Hana Biosciences to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference
01 April 2006 - 2:03AM
Business Wire
Hana Biosciences (AMEX:HBX) announced today that Mark Ahn, Ph.D.,
President & Chief Executive Officer, will present a company
update at the CIBC World Markets Annual Biotechnology &
Specialty Pharmaceuticals Conference on Tuesday, April 4, at 1:45
p.m. ET in Room 3.05 at The Millennium Broadway Hotel in New York
City. A live audio webcast of the presentation can be accessed on
the investor relations page of the company's website,
www.hanabiosciences.com. An audio replay of the presentation will
also be available for 90 days after the conference. About Hana
Biosciences Hana Biosciences, Inc. (AMEX:HBX) is a South San
Francisco, CA-based biopharmaceutical company that acquires,
develops, and commercializes innovative products to advance cancer
care. The company is committed to creating value by building a
world-class team, accelerating the development of lead product
candidates, expanding its pipeline by being the alliance partner of
choice, and nurturing a unique company culture. Additional
information on Hana Biosciences can be found at
www.hanabiosciences.com. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Hana's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual
outcomes and results to differ materially from these statements.
Among other things, there can be no assurances that any of Hana's
development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates,
the risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates, and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-KSB for the year ended Dec. 31,
2004. Hana assumes no obligation to update these statements, except
as required by law.
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Hana Biosciences (American Stock Exchange): 0 recent articles
More Hana Biosciences News Articles